Ophthalmic Goods · SIC 3851

Warby Parker Inc.

WRBY

Watch

Latest revenue

$242.4M

as of 2026-03-31

Latest net income

$3.2M

as of 2026-03-31

Net margin

1.3%

as of 2026-03-31

Community sentiment

Where do you think WRBY is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Keep private notes on WRBY — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to add your own notes

WRBY vs S&P 500 · rebased to 100

+14.2% / yr 5.5 pts / yr vs S&P 500(S&P 500 +19.7% / yr) 61.6% total
Compare:

Live market

delayed ≤15 min
$24.84
5.68%
Market cap
$2.81B
Enterprise value
$2.52B
P/E (trailing)
1713.6×
Forward P/E
P/B
7.48×
Dividend yield
0.0%
52-wk high
$31.00
52-wk low
$14.96
Beta
Shares out
113.2M

What this company does

AI

Item 1. Business Our Company Warby Parker is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. We stand for fun, creativity, and doing good in the world. Every day, our team of over 4,000 employees is focused on our mission to inspire and impact the world with vision, purpose, and style (without charging a premium for it). Our ultimate objective is to provide vision for all. As a pioneer of the direct-to-consumer model, we design our glasses in-house at our New York City headquarters and sell directly to customers, enabling us to make high-quality, designer eyewear more accessible, with simple, unified pricing…

AI summary unavailable — showing raw filing excerpt

Generated from WRBY's filing dated 2026-02-26

Key risks

AI

Item 1A. Risk Factors Investing in our Class A common stock involves a high degree of risk and uncertainty. You should consider and read carefully all of the risks and uncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operation”, before making an investment decision. The occurrence of any of the following risks and uncertainties could materially and adversely affect our business, financial condition, or results of operations. In such case, the trading price of our Class A…

AI summary unavailable — showing raw filing excerpt

Generated from WRBY's filing dated 2026-02-26

5.4
of 10

ActaClear Score

Neutral
#3 of 7 in Ophthalmic Goods
-0.4 · 5d
Profitability·25%
6.1
Growth·15%
6.7
Value·20%
2.2
Quality·20%
Momentum·20%
6.7

Computed from 5 years of SEC fundamentals + latest market data, ranked within Ophthalmic Goods (7 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.

7.26
Price / FV

Fair value · DCF

Deeply overvalued
~86% downside at this growth
17.2% / yr
-5%30%
Terminal growthWACC 9.8% · 10y forecast
Current price
$22.73
DCF fair value
$3.13
FCF base (last FY)
$1.64M
Net debt
$-286.36M
Methodology + caveats (click to expand)

Method. 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Beta defaults to 1.0 when not reported.

Why DCF is fragile. Treat the output as a thinking aid, not a verdict. Honest weaknesses of any DCF:

  • Growth is the dominant assumption. No one can foresee 10 years of growth — small changes in the slider can double or halve fair value. The reverse-DCF readout above tells you what the market is implicitly assuming; ask yourself whether that's realistic before trusting either number.
  • Terminal value dominates. In most DCFs, 60-80% of the answer comes from the terminal-value calculation — i.e., everything AFTER year 10. A 0.5pp change in terminal growth, or in WACC, can swing fair value by 20-30%.
  • WACC is itself a guess. We use a textbook CAPM cost of equity (Rf 4.3%, MRP 5.5%, β from the quote) plus a 6% pretax cost of debt — none of these are the company's actual marginal financing cost.
  • No moat / disruption modelling. The model assumes the company keeps earning whatever it earns today, compounding cleanly. Competitive shifts, regulatory action, and technology disruption can invalidate the forecast overnight.
  • Net income ≠ free cash flow. For capex-heavy names (semis, telcos) net income overstates distributable cash. For low-capex names (software) it understates. Both reduce the precision of the FV figure.
  • Reflexivity. A high stock price often becomes a self-fulfilling prophecy via better hiring, financing, and customer trust. DCF can't see this.

Take the DCF, the reverse-DCF implied growth, the historical multiples, and the community sentiment together. When they agree, conviction. When they disagree, the disagreement is the most informative thing on the page.